Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.50 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23132892 | 1.00 | HRH4 (0.50) | HRH4DOT1LACACBROCK2ROCK1 | |
| SCHEMBL23108626 | 0.82 | HRH4 (0.53) | HRH4DOT1LROCK2ROCK1CDC42BPB | |
| SCHEMBL24746253 | 0.82 | HRH4 (0.53) | HRH4DOT1LROCK2ROCK1CDC42BPB | |
| SCHEMBL23504191 | 0.82 | HRH4 (0.53) | HRH4DOT1LROCK2ROCK1CDC42BPB | |
| SCHEMBL4828769 | 0.81 | CHRNB2 (0.52) | HRH4DOT1LROCK2ROCK1CDC42BPB | |
| SCHEMBL4828913 | 0.81 | CHRNB2 (0.52) | HRH4DOT1LROCK2ROCK1CDC42BPB | |
| SCHEMBL4827822 | 0.81 | CHRNB2 (0.51) | HRH4DOT1L | |
| SCHEMBL23132875 | 0.81 | ACACB (0.43) | HRH4DOT1LACACBROCK2ROCK1 | |
| SCHEMBL4822898 | 0.81 | CHRNB2 (0.51) | HRH4DOT1L | |
| SCHEMBL23425828 | 0.80 | ACACB (0.43) | HRH4ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HRH4 462/4885DOT1L 3152/4885ACACB 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.